Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03035253 · ClinicalTrials.gov registry record · Phase 1
A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by OncoMed Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03035253 is a Phase 1 study that was terminated before completion, run by OncoMed Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT03035253, a Phase 1 study, was terminated before completion, sponsored by OncoMed Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and efficacy of an experimental drug, OMP-305B83, when given in combination with FOLFIRI or FOLFOX. OMP-305B83 is a humanized bispecific monoclonal antibody and was developed to target cancer stem cells. Based on preclinical studies, it is believed that OMP-305B83 may block the growth of cancer stem cells and may also impair the productive growth of new blood vessels, which tumors need to grow and spread. The study is sponsored by OncoMed Pharmaceuticals, which is referred to as OncoMed or the Sponsor.
Interventions
- DRUG FOLFIRI
- DRUG FOLFOX
- DRUG OMP-305B83
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03035253
The ClinicalTrials.gov registry entry for NCT03035253 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoMed Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which FOLFIRI is the first listed.
NCT03035253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03035253 about?
NCT03035253 is a clinical study titled "A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer". The purpose of this study is to test the safety and efficacy of an experimental drug, OMP-305B83, when given in combination with FOLFIRI or FOLFOX. OMP-305B83 is a humanized bispecific monoclonal antibody and was developed to target cancer stem cells. Based on preclinical studies, it is believed tha...
What is the current status of trial NCT03035253?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-12. Estimated completion is 2018-12.
What interventions are being tested in trial NCT03035253?
The interventions under investigation include: FOLFIRI (DRUG), FOLFOX (DRUG), OMP-305B83 (DRUG).
Who is sponsoring clinical trial NCT03035253?
This trial is sponsored by OncoMed Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.